Search

Displaying results 2241 - 2250 of 5419 in total
  1. Drug

    Gaboxadol

    go.drugbank.com/drugs/DB06554
    Investigational

    It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives. … Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing

  2. Drug

    Brinzolamide

    go.drugbank.com/drugs/DB01194
    Approved

    [A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate.

  3. Drug

    Thrombomodulin Alfa

    go.drugbank.com/drugs/DB05777
    Approved

    Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting...

  4. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.

  5. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    [L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. … Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.

  6. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    [A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986]

  7. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocy...

    Synonyms: Ig heavy chain V-III region BUR
  8. Drug

    Aliskiren

    go.drugbank.com/drugs/DB09026
    ApprovedInvestigational

    [A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.

  9. Drug

    Beraprost

    go.drugbank.com/drugs/DB05229
    Investigational

    It is also being studied for use in avoiding reperfusion injury.

  10. Drug

    Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16924
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen